

3.1 Lungenkarzinom**3.1.1 Funktionelle Operabilität****3.1.1.1 Präoperative Lungenfunktionswerte fraglich**

Puri V, Crabtree TD, Bell JM, et al. National Cooperative Group Trials of High-Risk Patients with Lung Cancer: Are They Truly High-Risk? *Ann Thorac Surg* 2014;97:1678-85.

Taylor MD, LaPar DJ, Isbell J M, et al. Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer. *J Thorac Cardiovasc Surg* 2014;147:738-46.

3.1.1.2 VATS-Lobektomie ist bei funktionell fraglich operablen Patienten möglich

Burt B, Kosinski A, Shrager J, et al. Thoracoscopic lobectomy is associated with acceptable morbidity and mortality in patients with predicted postoperative forced expiratory volume in 1 second or diffusing capacity for carbon monoxide less than 40 % of normal. *J Thorac Cardiovasc Surg* 2014; 148:19-28.

3.1.1.3 Prädiktion von kardiovaskulären Komplikationen bei lungenresezierenden Eingriff

Ferguson M, Saha-Chaudhuri P, Mitchell J, et al. Prediction of Major Cardiovascular Events After Lung Resection Using a Modified Scoring System. *Ann Thorac Surg* 2014;97:1135-41.

3.1.2 Präoperatives Staging**3.1.2.1 Revision der Guidelines der European Society of Thoracic Surgeons (ESTS)**

De Leyn P, Doooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. *Eur J Cardio-Thoracic Surg* 2014 1-12.

Verhagen Ad, Schuurbijs O, Looijen-Salamon M, et al. Mediastinal staging in daily practice: endosonography, followed by cervical mediastinoscopy. Do we really need both? *Interact CardioVasc and Thorac Surg* 17 2013 823-828.

3.1.2.2 Aktuelle Daten zur Sicherheit und Effektivität der Mediastinoskopie durch spezialisierte Thoraxchirurgen

Wei B, Bryant A, Minnich D, et al. The Safety and Efficacy of Mediastinoscopy when Performed by General Thoracic Surgeons, *Ann Thorac surg* 2014;97:1878-84.

3.1.2.3 Nachweis eines T3-Stadiums (Thoraxwand durch Ultraschall)

Tahirii M, Khareba M, Thiffault V, et al. Preoperative Assessment of Chest Wall Invasion in Non-Small Cell Lung Cancer using Surgeon-Performed Ultrasound. *Ann Thorac Surg* 2014; 98:984-9.

3.1.3 Therapieoptionen im Stadium I Lungenkarzinom**3.1.3.1 Parenchymsparende Resektionen**

Sakairi Y, Yoshino I, Yoshida S, et al. Pattern of Metastasis Outside Tumor-Bearing Segments in Primary Lung Cancer: Rationale for Segmentectomy. *Ann Thorax Surg* 2014;97:1694-700.

Yano M, Yoshida J, Koike T, et al. Survival of 1737 lobectomy-tolerable patients who underwent limited resection for cStage IA non-small-lung cancer. *Eur J Cardio-Thoracic Surg* 2014 1-8.

3.1.3.2 Stereotaktische Strahlentherapie bei Stadium I-Patienten

Guckenberger M, Allgäuer M, Appold S, et al. Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non-Small-Cell Lung Cancer in Routine Clinical Practice, *J Thorac Oncol* 2013;8:1050-1058.

Ricardi U, Frezza G, Filippi A, et al. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study. *Lung Cancer* 2014;84:248-53.

Mahmood S, Bilal H, Faivre-Finn C et al. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stag I non-small-cell lung cancer? *Interact CardioVasc and Thorac Surg* 17 2013 845-853.

3.1.4 Therapieoptionen Lungenkarzinom Stadium III

3.1.4.1 Empfehlungen des „American College of Chest Physicians (ACCP) 2013

Ramnath N, Dilling T, Harris L, et al. Treatment of Stage III Non-small Cell Lung Cancer. *Chest* 2013; 143 (5) (Suppl):e314S-e340S.

Hancock J, Rosen J, Moreno A, et al. Management of clinical Stage IIIA Primary Lung Cancers in the National Cancer Database. *Ann Thorac Surg* 2014; 98:424-32.

3.1.4.2 Prognose von Patienten mit “Skip”-Metastasen bei N2-Situation

Legras A, Mordant P, Arame A, et al. Long-Term Survival of Patients with pN2 Lung Cancer According to the Pattern of Lymphatic Spread. *Ann Thorac Surg* 2014;97:1156-62.

3.1.5 Op-Technik

3.1.5.1 Lymphknotendisektion entscheidend für die Prognoseabschätzung

Osarogiagbon R, Ogbata O, Yu X. Number of Lymph Nodes Associated with maximal reduction of Long-Term Mortality risk in Pathologic Node-Negative non-Small Cell Lung Cancer. *Ann Thorac Surg* 2014;97:385-93.

3.1.5.2 Präoperative Markierung von Lungenrundherden bei geplanter VATS-Resektion

Bommart S, Bourdin A, Marin G, et al. Impact of Preoperative Marking Coils on Surgical and Pathologic Management of Impalpable Lung Nodules. *Ann Thorac Surg* 2014;97:414-8.

3.1.5.3 Bronchusstumpverschluss: Handnaht versus Klammernaht

Zakkar M, Kanagasabay R, Hunt I. No evidence that manual closure of the bronchial stump has a lower failure rate than mechanical stapler closure following anatomical lung resection. *Interact CardioVasc and Thorac Surg* 18 2014 488-494.

3.1.5.4 VATS-Lobektomie versus offene Lobektomie bei Stadium I Lungenkarzinom

Stephens N, Rice D, Correa A, et al. Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical Stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases. *Eur J Cardio-Thorac Surg* 2014 1-7.

Zhang Z, Zhang Y, Feng H, et al. Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis. *Eur J Cardio-Thorac Surg* 44 2013 407-414.

3.1.6 Langzeitergebnisse und Prognosefaktoren nach Resektion

3.1.6.1 Frauen schneiden besser ab

Tong B, Kosinski A, Burfeind W, et al. Sex differences in early outcomes after lung cancer resection: Analysis of the Society of Thoracic Surgeons General Thoracic Database. *J Thorac Cardiovasc Surg* 2014; 148:13-8.

3.1.6.2 Langzeitergebnisse nach Resektion von Pancoast-Tumoren oder Tumoren mit Infiltration der Wirbelsäule

Collaud S, Waddell T, Yasufuku K, et al. Long-Term Outcome after En bloc Resection of Non-Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine, *J Thorac Oncol.* 2013;8:1538-1544.

3.1.6.3 Prognosen und chirurgische Strategien bei Tumoren mit fissurüberschreitendem Wachstum

Leuzzi G, Cesario A, Cafarotti S, et al. Surgical Treatment in Patient with Non-Small-Cell Lung Cancer with Fissure Involvement. *J Thorac Oncol.* 2014;9:97-108.

3.1.7. Postoperative Komplikationen

3.1.7.1 Nervus phrenicus bei Pneumonektomie unbedingt behalten

Kocher G, Mauss K, Carboni G, et al. Effect of phrenic Nerve palsy on Early Postoperative Lung Function after Pneumonektomie: A prospective Study. *Ann Thorac Surg* 2013;96:2015-20.

3.1.7.2 Mikrobiologische Untersuchung der Thoraxdrainagenspitzen zur Vorhersage von postoperativen Infektionen

Yamauchi Y, Isaka M, Maniwa T, et al. Chest Tube Tip Culture als a Predictor of Postoperative Infection in Lung Cancer Operations, *Ann Thorac Surg* 2013;96:1796-803.

3.1.8. Therapie von Patienten mit oligometastatischen Lungenkarzinomen

3.1.8.1 Welche Patienten kommen für ein kuratives Konzept in Frage?

Tönnies M, Pfannschmidt J, Bauer T, et al. Metastasektomy for Synchronous Solitary Non-Small Lung Cancer Metastases, *Ann Thorac Surg* 2014;98:249-56.

Endo C, Haumi T, Matsumura Y, et al. A Prospective Study of Surgical Procedures for Patients with Oligometastatic Non-Small Cell Lung Cancer, *Ann Thorac Surg* 2014; 98:258-64.

Ashworth A, Senan S, Palma D, et al. An Individual Patient Data metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer. *Clin Lung Cancer* 2014; 15, 346-55.

3.1.8.2 Bedeutung der Therapie des Primärtumors bei oligometastatischem Konzept

Parikh R, Cronin A, Kozono D, et al. Definitive Primary Therapy in Patients Presenting with Oligometastatic Non-Small Cell Lung Cancer, *Int J Radiation Oncol Biol Phys*, Vol. 89, No.4, pp. 880-887, 2014.

3.1.8.3 Adrenalectomie bei Patienten mit singulärer Nebennierenmetastase?

Sastry P, Toccock A, Coonar A, Adrenalectomy for isolated metastasis from operable non-small-cell lung cancer, *Interact CardioVasc and Thorac Surg* 18 (2014) 495-498.

3.1.9 Therapie des kleinzelligen Karzinoms

3.1.9.1 Langzeitergebnisse nach Resektion kleinzelliger Tumoren entspricht denen nicht kleinzelliger Tumoren

Lüchtenborg M, Riaz S, Lim E, et al. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009, *Thorax* 2014;69:269-273.

3.1.10 Nachsorge nach Lungenkarzinomresektion**3.1.10.1 Minimal-dose-CT als Alternative zur Röntgenaufnahme in der Nachsorge**

Hanna W, Paul N, Darling G, et al. Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer, *J Thorac Cardiovasc Surg* 2014;147:30-5.

3.1.10.2 Nachsorge nach Karzinoidtumoren: Aber wie?

Lou F, Sarkaria I, Pietanza C, et al. Recurrence of Pulmonary Carcinoid Tumors after Resection: Implications for postoperative Surveillance. *Ann Thorac Surg* 2013;96:1156-62.

3.2 Lungenmetastasen**3.2.1 Morbidität und Mortalität nach operativer Therapie von Patienten mit kolorektalen Lungenmetastasen**

Fiorentino F, Treasure T, Pulmonary Metastasectomy: Are Observational Studies Sufficient Evidence for Effectiveness? *Ann Thorac Surg* 2013;96:1129-31.

Rodriguez-Fuster A, Belda-Sanchis J, Aguilo R, et al. Morbidity and mortality in a large series of surgical patients with pulmonary metastases of colorectal carcinoma: a prospective multicenter Spanish study (GECMP-CCR-SEPAR), *Eur J Cardio-Thorac Surg* 45 (2014) 671-676.

3.3 Thymome**3.3.1 Prognosefaktoren bei Thymomen**

Ruffini E, Detterbeck F, Raemdonck D, et al. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. *Eur J Cardiothorac Surg*. 2014;46:361-8.

Ruffini E, Detterbeck F, Raemdonck D, et al. Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database. *J Thorac Oncol* 2014;9:541-548.

Marx A, Ströbel P, Badve S, et al. ITMIG Consensus Statement on the Use of The WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria and Reporting. *J Thorac Oncol*. 2014;9:596-611.

3.3.2 Prognosefaktoren bei Patienten mit neuroendokrinen Tumoren des Thymus

Cardillo G, Rea F, Lucchi M, et al. Primary Neuroendocrine Tumors of the Thymus: A Multicenter Experience of 35 Patients. *Ann Thorac Surg* 2012;94:241-6.

3.3.3 Therapie und Prognose von Patienten mit Thymomen und pleuraler Aussaat

Okuda K, Yano M, Yoshino I, et al, Thymoma Patients with Pleural Dissemination: Nationwide Retrospective Study of 136 Cases in Japan. *Ann Thorac Surg* 2014;97:1743-9.

3.3.4 Kann/muss der Nervus phrenicus bei der Thymomresektion geopfert werden?

Hamdi S, Mercier O, Fadel E, et al. Is scarifying the phrenic nerve during thymoma resection worthwhile? *Eur J Cardio-Thorac Surg* 45 (2014) e151-e155.

3.4 Mesotheliome
3.4.1 „Natürlicher“ Verlauf bei Patienten mit neu diagnostiziertem Pleuramesotheliom

Baud M, Strano S, Dechartres A, et al. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. *J Thorac Cardiovasc Surg* 2013;145:1305-11.

3.4.2 Wertigkeit von operativen Eingriffen beim Pleuramesotheliom

Bovolato P, Casadio C, Billè A, et al. Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma? *J Thorac Oncol* 2014;9:390-396.

3.4.3 Intensivierte Radiotherapie und Resektion bei Mesotheliomen („SMART“-Approach)

Cho J, Feld R, Leighl N, et al. A Feasibility Study Evaluation Surgery for mesothelioma after Radiation Therapy. *J Thorac Oncol* 2014;9:397-402.

3.5 Pleuraerguss/Pleuritis
3.5.1 Follow-Up bei unspezifischer Pleuritis

DePew Z, Verma A, Wigle D, et al. Nonspecific Pleuritis: Optimal Duration of Follow-Up. *Ann Thorac Surg* 2014;97:1867-71.

3.5.2 Lokalthherapie von medikamentös austerapierten kardial bedingten Pleuraergüssen: Talkumpleurodese versus PleurX-Kathetern

Freeman R, Ascoti A, Dake M et al. A Propensity-Matched Comparison of Pleurodesis or Tunneled Pleural Catheter for Heart Failure Patients with Recurrent Pleural Effusion. *Ann Thorac Surg* 2014;97:1872-7.

3.6 Postoperativer Chylothorax

Cho H J, Kim D K, Lee G D, et al. Chylothorax Complicating Pulmonary Resection for Lung Cancer: Effective management and Pleurodesis. *Ann Thorac Surg* 2014;97:408-13.

Takuwa T, Yoshida J, Ono S, et al. Low-fat diet management strategy for Chylothorax after pulmonary resection and lymph node dissection for primary lung cancer. *J Thorac Cardiovasc Surg* 2013;146:571-4.

Bryant A, Minnich D, Wei B, et al. The Incidence and management of postoperative Chylothorax after Pulmonary Resection and Thoracic Mediastinal Lymph Node Dissection. *Ann Thorac Surg* 2014;98:232-7.

3.7. Pneumothorax
3.7.1 Wann darf nach Pneumothorax wieder geflogen werden?

Bunch A, Duchateau F X, Verner L, et al. Commercial Air Tavel after Pneumothorax :A Review of the Literature. *Air Med J*; 2013 32, 268-74.

3.8 Lungenemphysem
3.8.1 Lungenvolumenreduktion bei Emphysem
3.8.1.1 Chirurgische Lungenvolumenreduktion resultiert in einer Normalisierung des Körpergewichts bei Untergewichtigen

Kim V, Kretschman D, Sternberg A, et al. Weight Gain after Lung Reduction Surgery is related to Improved Lung Function and Ventilatory Efficiency. *Am J Respir Crit Care Med* 2012; 186, 1109-16.

3.8.1.2 Langzeitergebnisse des Kanadischen Lungenvolumenreduktions-Trials

Agzarian J, Miller J, Kosa S, et al. Long-Term Survival Analysis of the Canadian Lung Volume Reduction Surgery Trial. *Ann Thorac Surg* 2013;96:1217-22

3.8.1.3 Abschätzung des Patientenpools für eine chirurgische Lungenvolumenreduktion

Akuthota P, Litmanovich D, Zutler M, et al. An Evidence-based Estimate on the Size of the Potential Patient Pool for Lung Volume Reduction Surgery. *Ann Thorax Surg* 2012; 94:205-11.

3.8.1.4 Einrichtung eines Emphyseboards verbessert die Ergebnisqualität

Rathinam S, Oey I, Steiner M, et al. The role of the emphysema multidisciplinary team in a successful lung volume reduction surgery programme. *Eur J Cardio-Thorac Surg* 2014 1-6.

3.8.2 Langzeitergebnisse der Bullektomie

Krishnamohan P, Shen R, Wigle D, et al. Bullectomy for Symptomatic or Complicated Giant Lung Bullae. *Ann Thorac Surg* 2014;97:425-31.

3.9. Zwerchfell**3.9.1 Nervus phrenicus-Rekonstruktion als Alternative zur Zwerchfell-
plikatur bei unilateraler Zwerchfellparese?**

Kaufman M, Elkwood A, Colicchio A, et al. Functional Restoration of Diaphragmatic Paralysis: An Evaluation of Phrenic Nerve Reconstruction. *Ann Thorax Surg* 2014;97:260-7.

3.10 Varia**3.10.1 Entfernung von Thoraxdrainagen: In Expiration oder in Inspiration?**

Bell R, Ovidia P, Abdullah F, et al. Chest Tube Removal: End-Inspiration oder End-Expiration? *J Trauma* 2001;50:674-677.

Cerfolio R J, Brant A, Skylizard L, et al. Optimal Technique for the removal of chest tubes after pulmonary resection. *J Thorac Cardiovasc Surg* 2013;145:1535-9.

3.10.2 Richtlinien zur Struktur und Organisation thoraxchirurgischer Einheiten

Brunelli A, Falcoz P E, et al. European Guidelines on structure and qualification of general thoracic surgery. *Eur J Cardio-Thorac Surg* 45 2014 779-786.